R
Roberta Bertorelle
Researcher at University of Padua
Publications - 104
Citations - 3598
Roberta Bertorelle is an academic researcher from University of Padua. The author has contributed to research in topics: Cancer & Temozolomide. The author has an hindex of 29, co-authored 98 publications receiving 3249 citations.
Papers
More filters
Journal ArticleDOI
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Alba A. Brandes,Enrico Franceschi,Alicia Tosoni,V. Blatt,Annalisa Pession,Giovanni Tallini,Roberta Bertorelle,Stefania Bartolini,Fabio Calbucci,Alvaro Andreoli,G. Frezza,Marco Leonardi,F. Spagnolli,Mario Ermani +13 more
TL;DR: PsPD has a clinical impact on chemotherapy-treated GBM, as it may express the glioma killing effects of treatment and is significantly correlated with MGMT status.
Journal ArticleDOI
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Alba A. Brandes,Alicia Tosoni,Giovanna Cavallo,Roberta Bertorelle,V Gioia,Enrico Franceschi,M Biscuola,V. Blatt,L. Crinò,Mario Ermani +9 more
TL;DR: The prolonged temozolomide schedule considered in the present study is followed by a high PFS-6 rate; toxicity is acceptable and further randomised trials should be conducted to confirm the efficacy of this regimen.
Journal ArticleDOI
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
Alba A. Brandes,Alicia Tosoni,Giovanna Cavallo,Michele Reni,Enrico Franceschi,Laura Bonaldi,Roberta Bertorelle,Marina Paola Gardiman,Claudio Ghimenton,P. Iuzzolino,Annalisa Pession,V. Blatt,Mario Ermani +12 more
TL;DR: In this paper, the authors evaluated correlations between 1p/19q deletions, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, and response rate to TMZ in this setting.
Journal ArticleDOI
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Marta Schirripa,Francesca Bergamo,Chiara Cremolini,Mariaelena Casagrande,Sara Lonardi,Giuseppe Aprile,D. Y. Yang,Federica Marmorino,Giulia Pasquini,Elisa Sensi,Cristiana Lupi,G. De Maglio,Nicla Borrelli,Stefano Pizzolitto,Gianpiero Fasola,Roberta Bertorelle,Massimo Rugge,Gabriella Fontanini,Vittorina Zagonel,Fotios Loupakis,Alfredo Falcone +20 more
TL;DR: BRAF mutation is associated with an extremely poor median RFS after liver resection and with higher probability of relapse and death, and knowledge of BRAF mutational status may optimise clinical decision making in mCRC patients potentially candidate to hepatic surgery.
Journal ArticleDOI
Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status
Chiara Menin,Maria Chiara Scaini,Gian Luca De Salvo,Martina Biscuola,Monica Quaggio,Giovanni Esposito,Claudio Belluco,Marco Montagna,Simona Agata,Emma D'Andrea,Donato Nitti,Alberto Amadori,Roberta Bertorelle +12 more
TL;DR: The data indicate that MDM2-SNP309 is a modifier of the age at colorectal cancer onset for patients whose tumors have a wild-type p53 gene.